MX341877B - Compuestos y métodos para tratar influenza. - Google Patents

Compuestos y métodos para tratar influenza.

Info

Publication number
MX341877B
MX341877B MX2012000230A MX2012000230A MX341877B MX 341877 B MX341877 B MX 341877B MX 2012000230 A MX2012000230 A MX 2012000230A MX 2012000230 A MX2012000230 A MX 2012000230A MX 341877 B MX341877 B MX 341877B
Authority
MX
Mexico
Prior art keywords
compounds
methods
treat influenza
influenza
prevention
Prior art date
Application number
MX2012000230A
Other languages
English (en)
Other versions
MX2012000230A (es
Inventor
Edward Semple J
Rossignol Jean-Francois
Original Assignee
Romark Laboratories L C *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43381033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX341877(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Romark Laboratories L C * filed Critical Romark Laboratories L C *
Publication of MX2012000230A publication Critical patent/MX2012000230A/es
Publication of MX341877B publication Critical patent/MX341877B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10F—INORGANIC SEMICONDUCTOR DEVICES SENSITIVE TO INFRARED RADIATION, LIGHT, ELECTROMAGNETIC RADIATION OF SHORTER WAVELENGTH OR CORPUSCULAR RADIATION
    • H10F55/00—Radiation-sensitive semiconductor devices covered by groups H10F10/00, H10F19/00 or H10F30/00 being structurally associated with electric light sources and electrically or optically coupled thereto
    • H10F55/18—Radiation-sensitive semiconductor devices covered by groups H10F10/00, H10F19/00 or H10F30/00 being structurally associated with electric light sources and electrically or optically coupled thereto wherein the radiation-sensitive semiconductor devices and the electric light source share a common body having dual-functionality of light emission and light detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Composite Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Esta invención se dirige a métodos para el tratamiento y prevención de infección por influenza al inhibir los procesos de maduración de virus HA de influenza empleado los compuestos de la fórmula I. También se dirige a combinaciones para el tratamiento y prevención de infección por influenza que comprende compuesto de la fórmula I y otros agentes.
MX2012000230A 2009-06-26 2010-06-23 Compuestos y métodos para tratar influenza. MX341877B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22089109P 2009-06-26 2009-06-26
PCT/US2010/039638 WO2010151577A1 (en) 2009-06-26 2010-06-23 Compounds and methods for treating influenza

Publications (2)

Publication Number Publication Date
MX2012000230A MX2012000230A (es) 2012-01-25
MX341877B true MX341877B (es) 2016-09-06

Family

ID=43381033

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016011352A MX391013B (es) 2009-06-26 2010-06-23 Compuestos y metodos para tratar influenza.
MX2012000230A MX341877B (es) 2009-06-26 2010-06-23 Compuestos y métodos para tratar influenza.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016011352A MX391013B (es) 2009-06-26 2010-06-23 Compuestos y metodos para tratar influenza.

Country Status (16)

Country Link
US (6) US9023877B2 (es)
EP (2) EP3895706A1 (es)
JP (3) JP5932640B2 (es)
KR (4) KR20180032689A (es)
CN (2) CN108042535A (es)
AP (1) AP2012006064A0 (es)
AU (2) AU2010264479B2 (es)
BR (2) BR122020003634B8 (es)
CA (3) CA2968113C (es)
EA (1) EA030679B1 (es)
ES (1) ES2914949T3 (es)
HK (1) HK1255283A1 (es)
MX (2) MX391013B (es)
PT (1) PT2445349T (es)
WO (1) WO2010151577A1 (es)
ZA (1) ZA201200263B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101760956B1 (ko) 2009-05-12 2017-07-24 로마크 레버러토리즈, 엘.씨. 할로알킬 헤테로아릴 벤즈아미드 화합물
KR20180032689A (ko) * 2009-06-26 2018-03-30 로마크 레버러토리즈, 엘.씨. 인플루엔자를 치료하기 위한 화합물 및 방법
WO2012061190A1 (en) * 2010-11-01 2012-05-10 Romark Laboratories L.C. Alkylsulfinyl-substituted thiazolide compounds
MX2013013115A (es) 2011-05-16 2014-02-27 Romark Lab Lc Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares.
AU2016201747B2 (en) * 2011-05-16 2017-06-01 Romark Laboratories, L.C. Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
AU2013201406B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP3006431B1 (en) * 2013-07-04 2019-01-30 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Tizoxanide carbamate and pharmaceutical use thereof
CN104771398B (zh) * 2014-01-09 2017-01-18 湖南大学 N‑[5‑（2‑硝基乙基）噻唑‑2‑基]苯甲酰胺及其医药用途
KR20170081228A (ko) * 2014-11-11 2017-07-11 로마크 레버러토리즈, 엘.씨. 티족사나이드, 그의 유사체 또는 염의 전구 약물을 이용한 치료 조성물 및 방법
BR112018004069A2 (pt) 2015-09-01 2021-07-13 First Wave Bio, Inc. composição farmacêutica sólida, preparação de enema compreendendo niclosamida, formulação de enema, uso de niclosamida e kit
HUE050601T2 (hu) 2016-03-31 2020-12-28 Romark Laboratories Lc Tiazolidvegyületek vírusfertõzések kezelésére
PH12018502142B1 (en) 2016-04-11 2023-08-11 Genfit Methods of treatment for cholestatic and fibrotic diseases
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US11173149B2 (en) 2017-04-18 2021-11-16 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase A3
CN107286149B (zh) * 2017-05-10 2021-02-12 南华大学 N-(5-胡椒基噻唑-2-基)哌啶基酰胺及其应用
CN107141267B (zh) * 2017-06-22 2019-04-09 湖南大学 N-(5-酰基噻唑-2-基)酰胺及其制备方法与应用
CN107235927B (zh) * 2017-06-22 2019-04-16 湖南大学 N-(5-酰基噻唑-2-基)哌嗪基酰胺及其医药用途
KR102077833B1 (ko) * 2018-12-10 2020-02-14 류형준 기능성 식품조성물
WO2020227004A1 (en) * 2019-05-03 2020-11-12 President And Fellows Of Harvard College Combination therapy for treating influenza virus infection
WO2021046446A1 (en) * 2019-09-06 2021-03-11 Yourchoice Therapeutics, Inc. Compositions and methods of use for enhancing fertility
CN118978524A (zh) * 2019-09-11 2024-11-19 绍兴君科臻元医药科技有限公司 硝唑尼特衍生物及其医药用途
JP2023512622A (ja) * 2020-01-21 2023-03-28 アカデミー オブ ミリタリー メディカル サイエンシズ ニタゾキサニド及びその活性型であるチゾキサニドのＳＡＲＳ－ＣｏＶ－２感染症の治療への適用
US20230241037A1 (en) * 2020-03-09 2023-08-03 1Globe Health Institute, Nanjing Cross-linked medication for treatment of coronaviral infection and method of treatment
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
RU2726070C1 (ru) * 2020-03-23 2020-07-08 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ патогенетической коррекции метаболических нарушений при инфекционном мононуклеозе, вызванном вирусом Эпштейна-Барр
WO2021202600A1 (en) * 2020-03-30 2021-10-07 The Scripps Research Institute Small molecule inhibitors of influenza hemagglutinin
EP4182304A1 (en) 2020-07-20 2023-05-24 Romark Laboratories, L.C. Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine
CN116367892A (zh) 2020-08-24 2023-06-30 罗马克实验室有限公司 噻唑化物抗冠状病毒的用途
WO2022109148A1 (en) * 2020-11-18 2022-05-27 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Small molecule inhibitors of sars-cov-2 infections
WO2022206084A1 (zh) * 2021-03-29 2022-10-06 北京大学 噻唑类化合物在制备治疗和预防癌症药物中的用途
MX2023011950A (es) * 2021-04-10 2024-01-08 Rhein Siegfried Sa De Cv Uso de nitazoxanida para la preparacion de medicamento para prevenir o tratar infeccion causada por coronavirus sars-cov-2.
CN115197164B (zh) * 2021-04-12 2025-04-01 杜心赟 新型噻唑类化合物及其制备方法和用途
CN113277994A (zh) * 2021-05-18 2021-08-20 杜心赟 噻唑类化合物及其制备方法和用途
WO2023198095A1 (zh) * 2022-04-12 2023-10-19 成都贝诺科成生物科技有限公司 一种硝基噻唑衍生物在制备抑制幽门螺杆菌的抑菌剂中的用途

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1177206A (en) 1967-11-28 1970-01-07 Pfizer & Co C Lung Antiviral Factor
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US4343945A (en) * 1979-01-23 1982-08-10 Olin Corporation 5-Benzamido-3-trichloromethyl-1,2,4-thiadiazoles and their use as herbicides, fungicides and insecticides
US4337081A (en) * 1979-01-23 1982-06-29 Olin Corporation 5-Amido-3-trihalomethyl-1,2,4-thiadiazoles and their use as herbicides
SU910628A1 (ru) 1980-04-22 1982-03-07 Гродненский государственный медицинский институт Способ получени 2-ациламинотиазолов
JPS56158703A (en) 1980-05-10 1981-12-07 Sankyo Co Ltd Fungicide
US4416683A (en) * 1980-09-16 1983-11-22 Eli Lilly And Company Benzamides, compositions and agricultural method
JPS649978A (en) 1987-07-02 1989-01-13 Shionogi & Co Perfluoroalkylisoxazole derivative
US4874864A (en) 1988-05-24 1989-10-17 Pfizer Inc. Benzamide protease inhibitors
US5169846A (en) * 1989-10-12 1992-12-08 Crooks Michael J Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators
WO1995020567A1 (en) 1994-01-28 1995-08-03 University Of Kentucky Research Foundation Codrugs as a method of controlled drug delivery
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
CN1072654C (zh) * 1994-04-13 2001-10-10 让-弗兰克伊斯·罗西格诺尔 苯甲酰胺衍生物,含所述衍生物的组合物及它们的用途
MX9604483A (es) * 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5968961A (en) * 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
TR199902733T2 (xx) 1997-05-07 2000-03-21 Romark Laboratories, L.C. Tizoksanit ve nitazoksanitten olu�an farmas�tik kompozisyonlar.
GB9725298D0 (en) 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
HU228111B1 (en) 1998-07-08 2012-11-28 Sanofi Aventis Deutschland Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US6849254B1 (en) * 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
US7229822B1 (en) 2000-02-29 2007-06-12 Univ Columbia Melanoma differentation associated gene-5 and vectors and cells containing same
DK1347971T3 (da) * 2000-12-21 2006-05-15 Bristol Myers Squibb Co Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
DE60208630T2 (de) * 2001-05-11 2006-08-17 Pfizer Products Inc., Groton Thiazolderivate und ihre Verwendung als cdk-Inhibitoren
WO2002092584A1 (en) 2001-05-14 2002-11-21 Nihon Nohyaku Co., Ltd. Thiadiazole derivatives, pesticides for agricultural and horticultural use and usage thereof
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2003335680A (ja) 2002-05-21 2003-11-25 Otsuka Pharmaceut Factory Inc Ａｃａｔ−１阻害剤
EP1510207A4 (en) 2002-06-05 2008-12-31 Inst Med Molecular Design Inc THERAPEUTIC MEDICAMENT AGAINST DIABETES
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
AU2003279010A1 (en) 2002-09-28 2004-04-19 Massachusetts Institute Of Technology Compositions and methods for delivery of short interfering rna and short hairpin rna
US6737382B1 (en) * 2002-10-23 2004-05-18 Nippon Soda Co. Ltd. Insecticidal aminothiazole derivatives
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
MXPA05009059A (es) * 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
JP2006521345A (ja) 2003-03-28 2006-09-21 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ニコチン性アセチルコリン受容体の正のアロステリック調節剤
RU2006104697A (ru) 2003-07-16 2006-06-27 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. (Jp) Лекарственное средство для лечения пигментации кожи
US20050090506A1 (en) * 2003-10-24 2005-04-28 Nippon Soda Co., Ltd. Insecticidal perfluoroalkylthiazole derivatives
US7683097B2 (en) 2004-05-27 2010-03-23 Propharmacon Inc. Topoisomerase inhibitors
UA90864C2 (en) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
US20060194853A1 (en) * 2004-10-08 2006-08-31 Rossignol Jean F Alkyl benzamides
US8357664B2 (en) * 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
WO2006110814A2 (en) * 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through inhibition the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
BRPI0608910A2 (pt) 2005-05-09 2010-02-17 Achillion Pharmaceuticals Inc uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada
EP2029138A1 (en) * 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
EP1910307A1 (en) 2005-06-27 2008-04-16 Exelixis, Inc. Pyrazole based lxr modulators
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
AU2006275849A1 (en) 2005-08-02 2007-02-08 Irm Llc 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors
ES2378473T3 (es) 2005-12-21 2012-04-12 Abbott Laboratories Compuestos antivirales
CN101448497B (zh) 2006-01-09 2013-07-10 罗马克实验室有限公司 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用
CA2649577A1 (en) 2006-04-28 2007-11-08 Transtech Pharma, Inc. Benzamide glucokinase activators
AU2007266535A1 (en) 2006-05-31 2007-12-06 Abbott Laboratories Thiazole compounds as cannabinoid receptor ligands and uses thereof
MX2008015457A (es) 2006-07-07 2009-01-16 Boehringer Ingelheim Int Derivados de heteroaril substituido en fenil y el uso de los mismos como agentes anti-tumorales.
WO2008033466A2 (en) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
JP2010511728A (ja) 2006-12-05 2010-04-15 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｉｌ−８受容体アンタゴニスト
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
AU2008299781B2 (en) * 2007-08-03 2013-11-14 Romark Laboratories L.C. Alkylsulfonyl-substituted thiazolide compounds
US8486987B2 (en) 2007-11-16 2013-07-16 University Of Medicine And Dentistry Of New Jersey Mechanism-based small-molecule parasite inhibitors
US20100081713A1 (en) * 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
US20100009970A1 (en) * 2008-03-19 2010-01-14 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
CN102089278A (zh) 2008-06-11 2011-06-08 Irm责任有限公司 用于治疗疟疾的化合物和组合物
AR073501A1 (es) 2008-09-08 2010-11-10 Boehringer Ingelheim Int Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
US20110224136A1 (en) 2008-11-19 2011-09-15 Ting Pauline C Inhibitors of diacylglycerol acyltransferase
US8835644B2 (en) * 2009-03-20 2014-09-16 University Of Virginia Patent Foundation Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials
KR101760956B1 (ko) 2009-05-12 2017-07-24 로마크 레버러토리즈, 엘.씨. 할로알킬 헤테로아릴 벤즈아미드 화합물
KR20180032689A (ko) * 2009-06-26 2018-03-30 로마크 레버러토리즈, 엘.씨. 인플루엔자를 치료하기 위한 화합물 및 방법

Also Published As

Publication number Publication date
CA2968113C (en) 2019-05-14
MX2012000230A (es) 2012-01-25
CA2968113A1 (en) 2010-12-29
US10363243B2 (en) 2019-07-30
CN102480967A (zh) 2012-05-30
KR20180032689A (ko) 2018-03-30
BRPI1014322A2 (pt) 2015-08-25
US20180078533A1 (en) 2018-03-22
KR20190120436A (ko) 2019-10-23
ZA201200263B (en) 2012-09-26
US11850237B2 (en) 2023-12-26
BR122020003634B1 (pt) 2021-03-16
JP5932640B2 (ja) 2016-06-08
JP2016172749A (ja) 2016-09-29
EP2445349A1 (en) 2012-05-02
EP3895706A1 (en) 2021-10-20
EP2445349A4 (en) 2012-12-05
ES2914949T3 (es) 2022-06-17
JP6464225B2 (ja) 2019-02-06
AU2010264479B2 (en) 2017-06-01
EA030679B1 (ru) 2018-09-28
US20160228415A1 (en) 2016-08-11
JP2012531420A (ja) 2012-12-10
WO2010151577A1 (en) 2010-12-29
AU2017221828A1 (en) 2017-09-21
US9345690B2 (en) 2016-05-24
CA2766642A1 (en) 2010-12-29
CA3038405A1 (en) 2010-12-29
CA3038405C (en) 2022-02-01
CA2766642C (en) 2017-09-05
EP2445349B1 (en) 2022-02-09
KR20120102570A (ko) 2012-09-18
BR122020003634B8 (pt) 2021-07-27
US10912768B2 (en) 2021-02-09
US9820975B2 (en) 2017-11-21
AU2010264479A1 (en) 2012-01-19
MX391013B (es) 2025-03-21
US20100330173A1 (en) 2010-12-30
KR101812054B1 (ko) 2017-12-27
KR20170141830A (ko) 2017-12-26
US20190307730A1 (en) 2019-10-10
US20210177809A1 (en) 2021-06-17
JP2017197552A (ja) 2017-11-02
PT2445349T (pt) 2022-05-16
CN108042535A (zh) 2018-05-18
AP2012006064A0 (en) 2012-02-29
US20150250768A1 (en) 2015-09-10
US9023877B2 (en) 2015-05-05
HK1255283A1 (zh) 2019-08-09
EA201270077A1 (ru) 2012-12-28
JP6188863B2 (ja) 2017-08-30

Similar Documents

Publication Publication Date Title
MX341877B (es) Compuestos y métodos para tratar influenza.
CR20110440A (es) Compuestos de piridazinona
EA201200917A1 (ru) Пролекарства ингибиторов плазменного калликреина
ECSP12011815A (es) Métodos sintéticos para compuestos espiro-oxoindol
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
UY32730A (es) Inhibidores de cyp17
CR20130024A (es) Compuestos heterocíclicos fusionados
CU24046B1 (es) Compuestos peptídicos que inhiben el virus de la hepatitis c
GT200900183A (es) Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina
CR20130281A (es) Compuesto bicíclico
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
DK2080516T3 (da) Anvendelse af isothiocyanatderivater som anti-myelom-midler
UY37378A (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
DOP2014000121A (es) Derivados de betulina
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
UY31925A (es) Isoquinolinas e isoquinolinonas sustituidas
HN2010000313A (es) Pirimidinas biciclicas fusionadas
ECSP13012600A (es) CO-cristales y Sales de Inhibidores de CCR3
CR20140078A (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
AR085308A1 (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
JO2999B1 (ar) مركب ثلاثي حلقي و استخدامه الدوائي
BR112015000392A2 (pt) novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório
SV2010003771A (es) Isoquinolinas e isoquinolinonas 6-sustituidas
PE20150348A1 (es) Compuestos de azetidina y piperidina utiles como inhibidores de pde10

Legal Events

Date Code Title Description
FG Grant or registration